Advances in the treatment of heart failure with preserved ejection fraction

dc.contributor.advisorKozma, Mariann
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorReghefaoui, Maiss Hamza Abdul Razzak
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentPriksz, Dániel
dc.contributor.opponentKurucz, Andrea
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Kardiológiai Intézethu_HU
dc.date.accessioned2021-09-17T08:50:09Z
dc.date.available2021-09-17T08:50:09Z
dc.date.created2021-05-25
dc.description.abstractHeart failure is a common condition that affects the elderly and is becoming the most common cause of hospitalization among the elderly nowadays. Its incidence has been increasing throughout the years and in particular HFpEF. The challenge with HFpEF lies in its treatment because, unlike HFrEF, the treatments for HFpEF have failed to show significant improvements in this group of patients. Many drug classes have been used for decades, but unfortunately with no significant improvements. Some newer drugs have been introduced recently and these drugs are discussed in detail in this work.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.coursespecOrvosbiológia-farmakológiahu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent39hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/321846
dc.language.isoenhu_HU
dc.subjectheart failurehu_HU
dc.subjectheart failure with preserved ejection fractionhu_HU
dc.subjectHFpEFhu_HU
dc.subjectTreatment of HFpEFhu_HU
dc.subjectHeart Failurehu_HU
dc.subjectHFhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleAdvances in the treatment of heart failure with preserved ejection fractionhu_HU
Fájlok